The Antidiabetic Drug Metformin Inhibits the Proliferation of Bladder Cancer Cells in Vitro and in Vivo

Metformin Suppresses Ovarian Cancer Growth and Metastasis with Enhancement of Cisplatin Cytotoxicity In Vivo

(2015) Ramandeep Rattan et al.   NEOPLASIA

Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer

(2013) Malte Rieken et al.   BJU INTERNATIONAL

Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

(2013) F. Morgillo et al.   CLINICAL CANCER RESEARCH

TSC1involvement in bladder cancer: diverse effects and therapeutic implications

(2013) Yanan Guo et al.   JOURNAL OF PATHOLOGY

The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo

(2012) K. Kato et al.   MOLECULAR CANCER THERAPEUTICS

Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis

(2012) Hiroshi Noto et al.   PLoS One

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Potential Role of CCND1 G870A Genotype as a Predictor for Urothelial Carcinoma Susceptibility and Muscle-Invasiveness in Taiwan

(2011) Hui-Hui Lin   CHINESE JOURNAL OF PHYSIOLOGY

Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma

(2010) Donna E. Hansel et al.   AMERICAN JOURNAL OF PATHOLOGY

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

(2010) Jose J. Mansure et al.   CANCER BIOLOGY & THERAPY

Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena

(2010) Begoña Martin-Castillo et al.   CELL CYCLE

Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target

(2010) J. G. Boyle et al.   DIABETIC MEDICINE

Cyclin D1 G870A Polymorphism Is Associated with Risk and Clinicopathologic Characteristics of Bladder Cancer

(2010) Lin Yuan et al.   DNA AND CELL BIOLOGY

Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin

(2010) Piotr J Wysocki et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

(2010) Zhijun Luo et al.   Future Oncology

Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer

(2009) C. M. Seager et al.   Cancer Prevention Research

Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer

(2009) F. M. Platt et al.   CLINICAL CANCER RESEARCH

Bladder cancer

(2009) Carl J Bischoff et al.   CURRENT OPINION IN ONCOLOGY

Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner

(2009) R. Rattan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Effect of sirolimus on urinary bladder cancer T24 cell line

(2009) Rosario Pinto-Leite et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase

(2008) M. Zakikhani et al.   Cancer Prevention Research

AMPK: a key regulator of energy balance in the single cell and the whole organism

(2008) D G Hardie   INTERNATIONAL JOURNAL OF OBESITY

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

(2008) I Ben Sahra et al.   ONCOGENE

Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties

(2008) Toni K Choueiri et al.   Nature clinical practice. Oncology